Web Analytics

fundsforNGOs

Grants and Resources for Sustainability

You are here: Home / Children / Pfizer Pediatric Pneumococcal Disease Research Grant (Saudi Arabia)

Pfizer Pediatric Pneumococcal Disease Research Grant (Saudi Arabia)

Deadline: 01-Jun-2026

Pfizer invites research proposals to study pediatric pneumococcal disease and serotype distribution in Saudi Arabia. Grants of up to $400,000 support surveillance studies using prospective or bidirectional cohort designs, focusing on disease burden, serotype variation, genetic evolution post-vaccination, and antibiotic resistance in children under five.

Overview

Pfizer’s research grant program supports projects addressing critical gaps in understanding pneumococcal disease epidemiology in children under five in Saudi Arabia. The initiative focuses on:

  • Surveillance of invasive and non-invasive pneumococcal disease
  • Serotype distribution and evolution following pneumococcal conjugate vaccine (PCV) programs
  • Antibiotic susceptibility patterns of Streptococcus pneumoniae
  • Utilization of samples collected between 2023–2029 from sterile sites (blood, cerebrospinal fluid, pleural fluid) and middle ear specimens

The program encourages robust study designs such as prospective or bidirectional cohort studies to produce actionable epidemiological data that informs public health strategies.

Objectives

  • Improve understanding of pediatric pneumococcal disease burden
  • Identify prevalent serotypes and track changes post-vaccination
  • Assess genetic evolution of pneumococci and potential vaccine escape variants
  • Monitor antimicrobial resistance trends in children under five
  • Generate data to guide vaccination policies and clinical management

Funding Details

  • Maximum funding per project: $400,000 USD (higher-cost projects considered case-by-case)
  • Project duration: Up to 3 years
  • Eligible costs: Study implementation, laboratory testing, sample collection and transport, personnel, and associated research expenses

Who is Eligible?

  • Organizations based in Saudi Arabia, including hospitals, academic institutions, and professional organizations
  • Principal Investigator (PI): Must hold an MD, PhD, advanced nursing, or pharmacy degree and be affiliated with the applying institution
  • Multicenter collaborations are encouraged
  • Institutions must be legally able to receive funding directly from Pfizer International LLC

Study Requirements

  • Conduct surveillance studies using prospective or bidirectional cohort designs
  • Include samples from sterile sites and middle ear specimens
  • Focus on children under 5 years of age
  • Generate actionable data to fill gaps in disease burden, serotype prevalence, and antibiotic resistance

Timeline

  • Application submission deadline: 1 June 2026
  • Grant award notification: September 2026
  • Project commencement: November 2026

How to Apply

  1. Confirm institutional eligibility to receive Pfizer funding
  2. Define study objectives, cohort design, and sample sources
  3. Prepare a detailed project proposal including timeline, budget, and methodological approach
  4. Submit the application before the deadline through the designated Pfizer portal

Tips for Applicants

  • Ensure all sample collection and study methods meet ethical and legal standards
  • Clearly outline multicenter collaboration roles if applicable
  • Provide a detailed plan for data analysis and interpretation
  • Demonstrate how the study addresses knowledge gaps in pneumococcal disease epidemiology in Saudi Arabia

Expected Impact

  • Strengthen national surveillance and epidemiological understanding of pneumococcal disease
  • Support evidence-based vaccination strategies
  • Contribute to antimicrobial stewardship and public health planning
  • Generate high-quality data for policymakers and healthcare providers

FAQs

  1. Who can be the Principal Investigator?
    An MD, PhD, advanced nursing, or pharmacy degree holder affiliated with the applying institution.
  2. Are multicenter studies allowed?
    Yes, collaborative studies with defined roles for each center are encouraged.
  3. What age group is included?
    Children under five years of age.
  4. What sample types are eligible?
    Blood, cerebrospinal fluid, pleural fluid, and middle ear specimens.
  5. Can the grant fund international collaborators?
    The primary applicant must be based in Saudi Arabia; collaborators may participate if roles are clearly defined.
  6. Is there flexibility in the budget?
    Up to $400,000 is standard; higher-cost projects may be considered individually.
  7. What is the main goal of this funding?
    To fill gaps in epidemiology, serotype distribution, and antimicrobial resistance knowledge for informed public health decisions in Saudi Arabia.

Conclusion

This Pfizer Pediatric Pneumococcal Disease Research Grant provides a strategic opportunity to strengthen surveillance and research capacity in Saudi Arabia. By generating high-quality, actionable data on pneumococcal disease and serotype distribution, funded projects will directly inform vaccination policies, clinical practices, and public health strategies, ultimately improving the health outcomes of children under five and contributing to a more evidence-driven healthcare system.

For more information, visit Pfizer.